New
Delhi: Roche Diagnostics India on Monday said it welcomed
Indian Council of Medical Research's communication regarding its COVID-19
antibody test for seroprevalence studies in India.
Dr Shravan Subramanyam, Managing Director, Roche Diagnostics India said, "Roche Diagnostics India welcomes ICMR's communication that cites making available Roche COVID-19 antibody test for seroprevalence studies in India."
According to Subramanyam, the study includes those on high-risk groups like healthcare workers - to plan the country's pandemic management efforts in the future. The lab-based antibody test that runs on fully automated Chemiluminescence Immunoassay (CLIA) analysers with estimated peak testing capacity of 0.5 million tests a day is being made available across National Accreditation Board for Testing and Calibration Laboratories (NABL) approved and government sites in India.
The Elecsys Anti-SARS-CoV-2 serology test that supports detection of antibodies against SARS-CoV-2 has received the Import License issued by the Central Drug Standard Control Organization (CDSCO), due to the emergency health situation in the public interest. (IANS)
Also watch: Ninong Ering, MLA, East Siang, Arunachal Pradesh in an exclusive chat with Oineetom